Glycosylation At Asn297
Glycosylation At Asn297 - Related Videos
01:25
Protein Glycosylation
0 Views •
2023
Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded. Glycosylation occurs in...
11:27
Analysis of SCAP N-glycosylation and Trafficking in Human Cells
0 Views •
Cited by 17 •
2016
We describe a modified method for membrane fraction isolation from human cells and sample preparation for the detection of SCAP N-glycosylation and total protein by using western blot. We further introduce a GFP-labeling method to monitor SCAP trafficking using confocal microscopy. This protocol can be used in regular biology laboratories.
09:54
Identification and Characterization of Protein Glycosylation using Specific Endo- and Exoglycosidases
0 Views •
Cited by 31 •
2011
Using specific glycosidases to remove sugars from glycoproteins followed by SDS-PAGE is a valuable method to detect glycan modifications on protein samples and is a good choice for initial glycobiology studies. Changes following deglycosylation can be detected as shifts in gel mobility or by staining with glycan sensitive reagents.
13:21
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
0 Views •
Cited by 6 •
2012
In this study, we describe an improved protocol for a multiplexed high-throughput antibody microarray with lectin detection method that can be used in glycosylation profiling of specific proteins. This protocol features new reliable reagents and significantly reduces the time, cost, and lab equipment requirements as compared to the previous procedure.
20:23
A Lectin HPLC Method to Enrich Selectively-glycosylated Peptides from Complex Biological Samples
0 Views •
Cited by 13 •
2009
Lectin-conjugated POROS beads were employed for HPLC. Glycopeptide standards served as positive and negative controls. MARS-14 depleted, trypsin-digested human plasma was chromatographed and flow-through (FT) and bound fractions collected for ESI-LC-MS/MS analyses. Glycopeptides were enriched in the bound fraction as compared to FT.
FAQs
The Asn297 glycan helps maintain the structural organization of the IgG Fc domain, which provides the physical context for binding partners. Because Fcγ receptors and C1q recognize this region, the glycan can influence how effectively an antibody engages those molecules. This structural role connects a molecular feature to downstream immune effector activity.
Interactions with Fcγ receptors determine how antibody-coated targets can engage immune cells, while interaction with C1q relates to complement activation. Consequently, the state of glycosylation at Asn297 can modulate several outcomes at once, including antibody-dependent cellular cytotoxicity, phagocytosis, and complement-mediated responses. This makes the site important when interpreting antibody function.
The conserved position of Asn297 makes it a consistent reference point for comparing IgG Fc glycosylation across antibodies or experimental conditions. Its location within the Fc region is functionally important because the glycan influences interactions with Fcγ receptors and C1q. Researchers can therefore relate a shared molecular site to differences in downstream effector activity.
Analysis of this site can help relate antibody Fc features to the way immune responses control pathogens and inflammation. By examining Asn297 glycosylation alongside outcomes such as cellular cytotoxicity, phagocytosis, or complement activation, researchers can study whether antibody regulation favors particular immune activities in a given infectious or immunological context.
Interpretation should include both cellular and complement-related outcomes. Fcγ receptor-associated effects can be considered through antibody-dependent cellular cytotoxicity and phagocytosis, whereas C1q-associated effects can be evaluated through complement activation. Considering these outcomes together helps determine whether glycosylation-associated differences affect cellular responses, complement responses, or both.
Glycosylation at Asn297 can be examined as a product attribute because it influences Fc interactions and resulting effector activity. Developers can use that relationship when designing antibodies with tailored activity and when assessing whether antibody preparations have the intended functional profile. The same principle supports evaluation of consistency in therapeutic antibody quality.